Excerpt

The July 28, 2008, workshop was moderated by Wylie Burke, chair of the Roundtable. Presentations followed by discussion occurred in four areas: the current status of genetic service delivery, strengths and challenges of the current system, new models for service delivery, and a vision for the future. Following these presentations, a panel of workshop speakers and participants brainstormed about a service delivery model for the future. The workshop did not address the ethical or legal considerations surrounding genomic innovations and the various new models of service delivery, including direct-to-consumer marketing of genetic tests.

Contents

• The National Academies
• Workshop Planning Committee
• Roundtable on Translating Genomic-based Research for Health
• Reviewers
• 1. Introduction
• 2. Genetic Service Delivery: The Current System and Its Strengths and Challenges
  • CURRENT STATUS OF GENETIC SERVICE DELIVERY
  • CHALLENGES OF DISPARITIES AND ACCESS
  • PATIENT EDUCATION AND COMMUNICATION
  • EDUCATIONAL PIPELINE AND WORKFORCE
  • DISCUSSION
• 3. New Models for Service Delivery
  • INFORMED MEDICAL DECISIONS, INC
  • NAVIGENICS
  • CINCINNATI CHILDREN’S HOSPITAL MEDICAL CENTER
  • DISCUSSION
• 4. Vision of the Future
  • DISCUSSION
• 5. Brainstorming on a Service Delivery Model for the Future
  • HEALTH CARE DELIVERY SYSTEM
  • HEALTH INFORMATION TECHNOLOGY
  • DATA COLLECTION
  • DISCUSSION
• 6. Concluding Remarks
• References
• Appendixes
  • A Workshop Agenda
  • B Speaker Biosketches

Erin Hammers, Rapporteur.

This project was supported by contracts between the National Academy of Sciences and American College of Medical Genetics (Unnumbered contract); American College of Physicians (Unnumbered contract); American Medical Association (Unnumbered contract); American Nurses Association (Unnumbered contract); AstraZeneca Pharmaceuticals, Inc. (Unnumbered contract); Blue Cross/Blue Shield Association (Unnumbered contract); Centers for Disease Control and Prevention (Contract No. 200-2005-13434); College of American Pathologists (Unnumbered contract); Department of Veterans Affairs (Contract No. V101(93) P-2238); Eli Lilly and Company (Contract No. LRL-0028-07); Food and Drug Administration (Contract No. 223012460); Genetic Alliance (Unnumbered contract); Genomics Health, Inc. (Unnumbered contract); GlaxoSmithKline, Inc. (Unnumbered contract); Health Systems Research, Inc. (Contract No. 07-H0116); National Human Genome Research Institute (Contract No. N01-OD-4-2139, TO#189); National Institute of Child Health and Human Development (Contract No. N01-OD-4-2139, TO#189); National Society of Genetic Counselors (Unnumbered contract); Secretary’s Advisory Committee on Genetics, Health and Society (Contract No. N01-OD-4-2139, TO#189); and UnitedHealthcare (Unnumbered contract). Any opinions, findings, conclusions, or recommendations expressed in this publication are those of the author(s) and do not necessarily reflect the views of the organizations or agencies that provided support for the project.

Suggested citation:

IOM (Institute of Medicine). 2009. Innovations in service delivery in the age of genomics: Workshop summary. Washington, DC: The National Academies Press.

NOTICE: The project that is the subject of this report was approved by the Governing Board of the National Research Council, whose members are drawn from the councils of the National Academy of Sciences, the National Academy of Engineering, and the Institute of Medicine.